CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5978-5991

  Ruggeri, Bruce ^a   Singh, Jasbir ^a   Gingrich, Diane ^a   Angeles, Thelma ^a   Albom, Mark ^a   Chang, Hong ^a   Robinson, Candy ^a   Hunter, Kathryn ^a   Dobrzanski, Pawel ^a   Jones Bolin, Susan ^a   Aimone, Lisa ^a   Klein Szanto, Andres ^c   Herbert, Jean Marc ^d   Bono, Francoise ^d   Schaeffer, Paul ^d   Casellas, Pierre ^d   Bourie, Bernard ^d   Pili, Roberto ^b   Isaacs, John ^b   Ator, Mark ^a   Hudkins, Robert ^a   Vaught, Jeffry ^a   Mallamo, John ^a   Dionne, Craig ^a   more..

^a Cephalon Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MATRIGEL; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AORTA; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST CARCINOMA; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; GRANULOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CARCINOMA; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; UMBILICAL VEIN; XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0141842637     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
2. Hanahan, D. Signaling vascular morphogenesis and maintenance. Science (Wash. DC), 277: 48-50, 1997.
3. Griffioen, A. W., and Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev., 52: 237-268, 2000.
4. Folkman J. In: J. E. Holland, I. E. Frei, J. Bast, D. Kufe, R. Pollock, and R. Weichselbaum (eds.), Cancer Medicine, Ed. 5, pp. 132-152. Ontario, Canada: B. C. Dekker, Inc., 2000.
5. Korpelainen, E. I., and Alitalo, K. Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell Biol., 10: 159-164, 1998.
6. Ferrara, N., and Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
7. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
8. McMurtrey, G. H-P., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/akt signal transduction pathway. J. Biol. Chem., 273: 30336-30343, 1998.
9. Rahim, N., Dayanir, V., and Lashkari, K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 modulates mitogenic activity of VEGF-R2 in endothelial cells. J. Biol. Chem., 275: 16986-16992, 2000.
10. Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T. F., Pelletier and Ferrara, N. Analysis of biological effects and signaling properties of Flt-1 (VEGF-R1) and KDR (VEGF-R2). J. Biol. Chem., 276: 3222-3230, 2001.
11. Gille, H., Kowalski, J., Yu, L., Chen, H., Pisabarro, M. T., Davis-Smyth, T., and Ferrara, N. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J., 19: 4064-4073, 2000.
12. Hiratsuka, S., Maru, Y., Okada, A., Seiki, M., Noda, T., and Shibuya, M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res., 61: 1207-1213, 2001.
13. Aliello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., and Smith, L. E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA, 92: 10457-10461, 1995.
14. Clauss, M., Gerlach, M., Gerlach, H., Brett, J., Wang, F., Familletti, P. C., Pan, Y. C., Olander, J. V., Connolly, D. T., and Stern, D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med., 172: 1535-1545, 1990.
15. Wang, H., and Keiser, J. A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle Cells role of Flt-1. Circ. Res., 83: 832-840, 1998.
16. Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejadi, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., Hendrix, J., Hackett, N. R., Crystal, R. G., Moore, M. A., Werb, Z., Lyden, D., and Rafii, S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med., 8: 841-849, 2002.
17. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compemolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., DiPalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., Vandendriessche, T., Ponten, A., Eriksson, U., Plate, K. H., Foidart, J-M., Schaper, W., Charnock-Jones, D. S., Hicklin, D. J., Herbert, J-M., Collen, D., and Persico, M. G. Synergism between VEGF and placental growth factor (PIGF) contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med., 7: 575-583, 2001.
18. Beasley, N. J. P., Prevo, R., Banerji, S., Leek, R. D., Moore, J., van Trappen, P., Cox, G., Harris, A. L., and Jackson, D. G. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res., 62: 1315-1320, 2002.
19. Mattila, M. M-T., Ruohola, J. K., Karpanen, T., Jackson, D. G., Altitalo, K., and Härkönen, P. L. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer, 98: 946-951, 2002.
20. White, J. D., Hewett, P. W., Kosuge, D., McCulloch, T., Enholm, B. C., Carmichael, J., and Murray, J. C. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res., 62: 1669-1675, 2002.
21. Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E., and Alitalo, K. Lymphangiogenesis and cancer metastasis. Nat. Rev. (Cancer), 2: 573-583, 2002.
22. Dias, S., Choy, M., Alitalo, K., and Rafii, S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 99: 2179-2184, 2002.
23. Inoue, M., Hager, J. H., Ferrara, N., Gerber H-P. and Hanahan, D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell, 1: 193-202, 2002.
24. Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D., and Johnson, R. S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res., 59: 1592-1598, 1999.
25. Deplanque, G., and Harris, A. L. Anti-angiogenic agents: clinical trial design and therapies in development. Eur. J. Cancer, 36: 1713-1724, 2000.
26. Kerbel, R. S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol., 19 (Suppl.): 45s-51s, 2001.
27. Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov., 1: 415-426, 2002.
28. Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., Winkler, M., and Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57: 4593-4599, 1997.
29. Brekken, R. A., Overholser, J. P., Stastny, V. A., Waltenberger, J., Minna, J. D., and Thorpe, P. E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res., 60: 5117-5124, 2000.
30. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P., and Hicklin, D, J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res., 59: 5209-5218, 1999.
31. Ke, L. D., Fueyo, J., Chen, X., Steck, P. A., Shi, Y-X., Im, S-A., and Yung, W. K. A. A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int. J. Oncol., 12: 1391-1396, 1998.
32. Parry, T. J., Cushman, C., Gallegos, A. M., Agrawal, A. B., Richardson, M., Andrews, L. E., Maloney, L., Mokler, V. R., Wincott, F. E., and Pavco, P. A. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res., 27: 2569-2577, 1999.
33. Holash, J., Davis, S., Papadopopulou, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J. P., Daly, T., Wiegand, S. J., Yancopoulos, G. D., and Rudge, J. S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA, 99: 11393-11398, 2002.
34. Sun, L., and McMahon, G. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov. Today, 5: 344-354, 2000.
35. Wood, J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., Persohn, E., Rosel, J., Schnell, C., Stover, D., Theuer, A., Towbin, H., Weger, F., Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K-H., Schneider, M. R., Drevs, J., Martiny-Baron, G., Totzke, F., and Marme, D. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 60: 2178-2189, 2000.
36. Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Muller, M., Wood, J., Martiny-Baron, G., Unger, C., and Marme, D. Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density and blood flow in a murine renal cell carcinoma model. Cancer Res., 60: 4819-4824, 2000.
37. Drevs, J., Muller-Driver, R., Wittig, C., Fuxius, S., Esser, N., Hugenschmidt, H., Konerding, M. A., Allegrini, P. R., Wood, J., Hennig, J., Unger, C., and Marme, D. PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, effects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res., 62: 4015-4022, 2002.
38. Baker, C. H., Solorzano, C. C., and Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 62: 1996-2003, 2002.
39. Fabbro, D., Ruetz, S., Bodis, S., Pruschy, M., Csermak, K., Man, A., Compochiaro, P., Wood, J., O'Reilly, T., and Meyer, T. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Discov., 15: 17-28, 2000.
40. Hennequin, L. F., Stokes, E. S., Thomas, A. P., Johnstone, C., Ple, P. A., Ogilvie, D. J., Du, M., Wedge, S. R., Kendrew, J., and Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem., 45: 1300-1312, 2002.
41. Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J. O., Musgrove, H. L., Graham, G. A., Hughes, G. D., Thomas, A. P., Stokes, E. S. E., Curry, B., Richmond, G. H. P., Wadsworth, P. F., Bigley, A. L., and Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res., 62: 4645-4655, 2002.
42. Mendel, D. B., Laird, A. D., Xin, X., Abrams, T. J., Li, G., Schreck, R. E., Carver, J., Louie, S. G., Ngai, T. J., Lee, L. B., Nannini, M. A., Murray, L. J., Tang, C., Mc Mahon, G., and Cherrington, J. M. In vivo anti-tumor and mechanism of action studies of SU11248, a potent and selective inhibitor of the VEGF and PDGF receptors. Proc. Am. Assoc. Cancer Res., 43: 5349, 2002.
43. Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R. E., Abrams, T. J., Ngai, T. J., Lee, L. B., Murray, L. J., Carver, J., Chan, E., Moss, K. G., Haznedar, J. O., Sukbuntherng, J., Blake, R. A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G., and Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic and pharmacodynamic relationship. Clin. Cancer Res., 9: 327-337, 2003.
44. Jani, J. P., Beebe, J. S., Emerson, E., Gant, T., Goodwin, P., Higdon, C., Hillerman, S., Intrieri, C., Knauth, L., Marx, M., Noe, M., Rossi, A. M., Savage, D., Atherton, J., Floyd, E., Harriman, S., and Roberts, G. CP-547, 632, a novel VEGF-R2 tyrosine kinase inhibitor for cancer therapy. Proc. Am. Assoc. Cancer Res., 43: 5354, 2002.
45. Gingrich, D. E., and Hudkins, R. L. Selected fused pyrrolocarbazoles. U.S. Patent WO 0217914, issued March 17, 2002.
46. Hudkins, R. J., and Knight, E., Jr. Fused pyrrolocarbazoles. U.S. Patent 5.705,511, issued January 6, 1998.
47. Rotin, D., Margolis, B., Mohammadi, M., Daly, R. J., Daum, G., Li, N., Fischer, E. H., Burgess, W. H., Ullrich, A., and Schlessinger, J. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C-γ. EMBO J., 11: 559-567, 1992.
48. Angeles, T. S., Steffler, C., Bartlett, B. A., Hudkins, R. L., Stephens, R. M., Kaplan, D. R., and Dionne, C. A. Enzyme-linked immunosorbent assay for TRKA tyrosine kinase activity. Anal. Biochem., 236: 49-55, 1996.
49. Pitt, A. M., and Lee, C. High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate. J. Biomol. Screen., 1: 47-51, 1996.
50. Maroney, A. C., Finn, J. P., Connors, T. J., Durkin, J. T., Angeles, J., Gessner, G., Xu, Z., Meyer, S. L., Savage, M. J., Greene, L. A., Scott, R. W., and Vaught, J. L. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem., 276: 25302-25308, 2001.
51. Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghisom, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H. R., and Folkman, J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA, 94: 861-866, 1997.
52. Vailhe, B., Vittet, D., and Feige, J. J. In vitro models of vasculogenesis and angiogenesis. Lab. Investig., 81: 439-452, 2001.
53. Ilan, N., Mahooti, S., and Madri, J. A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J. Cell Sci., 111: 3621-3631, 1998.
54. Malinda, K. M., Nomizu, M., Chung, M., Delgado, M., Kuratomi, Y., Yamada, Y., Kleinman, H. K., and Ponce, M. L. Identification of laminin α1 and β1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J., 13: 53-62, 1999.
55. Montesano, R., Orci, L., and Vassalli, P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J. Cell Biol., 97: 1648-1652, 1983.
56. Brown, K. J., Maynes, S. F., Bezos, A., Maguire, D. J., Ford, M. D., and Parish, C. R. A novel in vitro assay for human angiogenesis, Lab. Investig., 75: 539-555, 1996.
57. Nicosia, R. F., Lin, Y. J., Hazelton, D., and Qian, X. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am. J. Pathol., 151: 1379-1386, 1997.
58. Zhu, W. H., Guo, X., Villaschi, S., and Nicosia, R. F. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab. Investig., 80: 545-555, 2000.
59. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S., and Martin, G. R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Investig., 67: 519-528, 1992.
60. Pili, R., Robinson, C., Morris, C. A., Dionne, C. A., Isaacs, J. T., and Ruggeri, B. A. CEP-5214. a novel orally active inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, inhibits VEGF-induced angiogenesis and prostate tumor growth in vivo. Clin. Cancer Res., 7 (Suppl.): 3658s, 2001.
61. Colville-Nash, P. R., Alani, C. A. S., Appleton, I., Brown, J. R., Seed, M. P., and Willoughby, D. A. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. J. Pharmacol. Exp. Ther., 274: 1463-1472, 1995.
62. George, D. J., Dionne, C. A., Jani, J., Angeles, T., Murakata, C., Lamb, J., and Isaacs, J. T. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res., 59: 2395-2401, 1999.
63. Morita, T., Shinora, N., and Tokue, A. Anti-tumor effect of a synthetic analogue of fumagillin on murine renal cell carcinoma. Br. J. Urol., 74: 416-421, 1994.
64. Younes, E., Haas, G. P., Dezso, B., Ali, E., Maughan, R. L., Kukuruga, M. A., Montecillo, E., Pontes, J. E., and Hillman, G. G. Local tumor irradiation augments the response to IL-2 therapy in a marine renal adenocarcinoma. Cell. Immunol., 165: 243-251, 1995.
65. Angelov, L., Salhia, B., Roncari, L., McMahon, G., and Guha, A. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res., 59: 5536-5541, 1999.
66. Ruggeri, B., Singh, J., Hudkins, R., Gingrich, D., Angeles, T., Robinson, C., Chang, H., Hunter, K., Dobrzanski, P., Pritchard, S., Vaught, J., and Dionne, C. CEP-7055: an orally-active VEGF-R kinase inhibitor with potent anti-angiogenic activity and anti-tumor efficacy against human tumor xenograft growth. Proc. Am. Assoc. Cancer Res., 43: 5347, 2002.
67. Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., and Jain, R. K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med., 2: 992-997, 1996.
68. Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., and Jain, R. K. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducing factor 1α →hypoxia response element→ VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res., 60: 6248-6252, 2000.
69. Salven, P., Hattori, K., Heissig, B., and Rafii, S. Interieukin-1α promotes angiogenesis in vivo via VEGF-R2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J., 16: 1471-1473, 2002.
70. Goddard, L. E., Clermont, A. C., Bursellm, D., Jones-Bolin, S., Ruggeri, B., and Bursell, S. E. Retinal vascular leakage in early diabetes is normalized in vivo by the oral VEGF receptor kinase inhibitor, CEP-7055. Investig. Ophthalmol. Vis. Sci., 43 (Suppl.): 3862, 2002.
71. Jung, Y. D., Ahmad, S. A., Akagi, Y., Takahashi, Y., Liu, W., Reinmuth, N., Shaheen, R. M., Fan, F., and Ellis, L. M. Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev., 19: 147-157, 2000.
72. Giordano, F. J., and Johnson, R. S. Angiogenesis: the role of the microenvironment in flipping the switch. Curr. Opin. Genet. Dev., 11: 35-40, 2001.
73. Gale, N. W., and Yancopoulos, G. D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev., 13: 1055-1066, 1999.
74. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., and Augustin, H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res., 60: 1388-1393, 2000.
75. Stratman, A., Acker, T., Burger, A. M., Amann, K., Risau, W., and Plate, K. H. Differential inhibition of tumor angiogenesis by TIE-2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int. J. Cancer, 91: 273-282, 2001.
76. Zhu, W-H., MacIntyre, A., and Nicosia, R. F. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model. Am. J. Pathol., 161: 823-830, 2002.
77. Laird, A. D., Christensen, J. G., Li, G., Carver, J., Mith, K., Xin, X., Moss, K. G., Louie, G., Mendel, D. B., and Cherrington, J. M. SU6668 inhibits FLK-I/KDR and PDGF-RB in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J., 16: 681-690, 2002.
78. Fabbro, D., and Manley, P. W. SU-6668 SUGEN. Curr. Opin. Investig. Drugs, 2: 1142-1148, 2001.